# EDGAR Filing Document

**Accession Number:** 0001236927
**File Stem:** 0001104659-25-120702
**Filing Date:** 2025-12
**Character Count:** 10196
**Document Hash:** ac3bef94e4e21666c339899c97fdbeef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-120702.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001104659-25-120702

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251212

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Canticle Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001673226

**ORGANIZATION NAME:**
- **EIN:** 453050834
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89582
- **FILM NUMBER:** 251568952

**BUSINESS ADDRESS:**
- **STREET 1:** 500 OFFICE CENTER DRIVE
- **STREET 2:** SUITE 400
- **CITY:** FORT WASHINGTON
- **STATE:** PA
- **ZIP:** 19034
- **BUSINESS PHONE:** 949-725-4277

**MAIL ADDRESS:**
- **STREET 1:** 500 OFFICE CENTER DRIVE
- **STREET 2:** SUITE 400
- **CITY:** FORT WASHINGTON
- **STATE:** PA
- **ZIP:** 19034

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Madrigal Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20160427
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FRIEDMAN PAUL A
- **CENTRAL INDEX KEY:** 0001236927

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O INCYTE CORPORATION
- **STREET 2:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**MADRIGAL PHARMACEUTICALS, INC.**

*(Name of Issuer)*

**Common Stock, Par Value $0.0001 Per Share**

*(Title of Class of Securities)*

**558868105**

*(CUSIP Number)*

**Paul A. Friedman, M.D.**<br>c/o Madrigal Pharmaceuticals, Inc.<br>4 Tower Bridge, 200 Barr Harbor Dr, #200<br>West Conshohocken PA 19428<br>(267) 824-2827

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **558868105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Paul A Friedman, M.D.** | Name of reporting person<br>**Paul A Friedman, M.D.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1159291.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**655540.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1159291.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**655540.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1814831.00** | Aggregate amount beneficially owned by each reporting person<br>**1814831.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.8%** | Percent of class represented by amount in Row (11)<br>**7.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The amount reported in rows 7, 9 and 11 includes (i) 165,115 shares of Common Stock held of record by the Reporting Person, (ii) 291,530 shares of Common Stock subject to stock options that are exercisable within 60 days of December 10, 2025, (iii) 6,667 shares of Common Stock subject to restricted stock units that vest within 60 days of December 10, 2025, (iv) 436,868 shares of Common Stock held of record by the Reporting Person's spouse, (v) 252,665 shares of Common Stock subject to stock options held by the Reporting Person's spouse that are exercisable within 60 days of December 10, 2025 and (vi) 6,446 shares of Common Stock subject to restricted stock units held by the Reporting Person's spouse that vest within 60 days of December 10, 2025.

(2) The amount reported in rows 8, 10 and 11 includes shares of Common Stock held of record by SQN, LLC.  The Reporting Person is a managing member of SQN and may be deemed to share voting and investment power over Common Stock that is owned by SQN.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, Par Value $0.0001 Per Share

**(b) Name of Issuer:**
MADRIGAL PHARMACEUTICALS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, PA, 19428

This Amendment No. 2 ("Amendment No. 2") amends the Statement on Schedule 13D filed with the SEC on August 1, 2016, as amended on October 17, 2019 (the "Original Statement"), which relates to shares of common stock, par value $0.0001 per share ("Common Stock"), of Madrigal Pharmaceuticals, Inc., a Delaware corporation with a class of securities registered under Section 12 of the 1934 Act (the "Issuer"). The principal executive offices of the Issuer are located at 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania, 19428. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Except as otherwise described herein, the information contained in the Original Statement remains in effect. Capitalized terms used but not defined in this Amendment No. 2 shall have the respective meanings set forth with respect thereto in the Original Statement.

**Item 4. Purpose of Transaction**

No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate number and percentage of shares of Common Stock beneficially owned by the Reporting Persons is based on 22,711,420 shares of Common Stock outstanding as of October 30, 2025, as reported in the Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025 by the Issuer, and is set forth in boxes 11 and 13 of the second part of the cover page to this Statement, and such information is incorporated herein by reference.

**(b)**
The amounts of Common Stock as to which the Reporting Person has sole voting power, shared voting power, sole dispositive power and shared dispositive power is set forth in boxes 7, 8, 9 and 10, respectively, on the second part of the cover page to this Statement, and such information is incorporated herein by reference.

**(c)**
The Reporting Person has not effected any transactions related to the Common Stock during the past 60 days, except for the dispositions set forth in Annex I of this Schedule 13D (all of which previously have been reported or will be reported on Form 4s filed pursuant to Section 16(a) of the Act):

                                                                             Annex I

                                    Information With Respect to Transactions of Common Stock

Reporting Person     Date of            Number       Type of        Price Per         Where and
Who Effected The    Transaction     of Shares     Security      Share*             How
Transaction                                                                                                     Transaction
                                                                                                                        Was
                                                                                                                        Effected

Paul A. Friedman     12/10/2025       24,800        Common     $552.1838      Open market
                                                                             Stock                                  sale on
                                                                                                                        NASDAQ

Spouse                    12/10/2025       18,650        Common     $552.1487       Open market
                                                                             Stock                                  sale on
                                                                                                                        NASDAQ

Spouse                    12/10/2025       5,455          Common      NA                  Charitable
                                                                            Stock                                   Gift

*The price reported is a weighted average price for shares sold in multiple transactions on the same date. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price in such range.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information in Item 3 is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Paul A Friedman, M.D.

**Signature:** /s/ Paul A. Friedman, M.D.

**Name/Title:** Paul A. Friedman, M.D.

**Date:** 12/12/2025